Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.67
EXEL's Cash to Debt is ranked higher than
58% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. EXEL: 0.67 )
EXEL' s 10-Year Cash to Debt Range
Min: 0.64   Max: No Debt
Current: 0.67

Equity to Asset 0.01
EXEL's Equity to Asset is ranked higher than
51% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. EXEL: 0.01 )
EXEL' s 10-Year Equity to Asset Range
Min: -0.7   Max: 0.8
Current: 0.01

-0.7
0.8
F-Score: 3
Z-Score: -6.28
M-Score: -2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1137.70
EXEL's Operating margin (%) is ranked higher than
56% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. EXEL: -1137.70 )
EXEL' s 10-Year Operating margin (%) Range
Min: -673.24   Max: 30.91
Current: -1137.7

-673.24
30.91
Net-margin (%) -1343.51
EXEL's Net-margin (%) is ranked higher than
55% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. EXEL: -1343.51 )
EXEL' s 10-Year Net-margin (%) Range
Min: -781.03   Max: 26.14
Current: -1343.51

-781.03
26.14
ROE (%) -304.11
EXEL's ROE (%) is ranked higher than
51% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. EXEL: -304.11 )
EXEL' s 10-Year ROE (%) Range
Min: -2156.15   Max: -35.6
Current: -304.11

-2156.15
-35.6
ROA (%) -54.78
EXEL's ROA (%) is ranked higher than
61% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. EXEL: -54.78 )
EXEL' s 10-Year ROA (%) Range
Min: -134.14   Max: 20.08
Current: -54.78

-134.14
20.08
ROC (Joel Greenblatt) (%) -4877.77
EXEL's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. EXEL: -4877.77 )
EXEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3659.99   Max: 736.4
Current: -4877.77

-3659.99
736.4
Revenue Growth (%) -53.70
EXEL's Revenue Growth (%) is ranked higher than
58% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. EXEL: -53.70 )
EXEL' s 10-Year Revenue Growth (%) Range
Min: -53.7   Max: 25.6
Current: -53.7

-53.7
25.6
EBITDA Growth (%) 16.90
EXEL's EBITDA Growth (%) is ranked higher than
90% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. EXEL: 16.90 )
EXEL' s 10-Year EBITDA Growth (%) Range
Min: -44.8   Max: 17.8
Current: 16.9

-44.8
17.8
EPS Growth (%) 16.10
EXEL's EPS Growth (%) is ranked higher than
89% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. EXEL: 16.10 )
EXEL' s 10-Year EPS Growth (%) Range
Min: -42.1   Max: 16.1
Current: 16.1

-42.1
16.1
» EXEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

EXEL Guru Trades in Q3 2013

Jean-Marie Eveillard 1,173,300 sh (+9.32%)
» More
Q4 2013

EXEL Guru Trades in Q4 2013

Steven Cohen 14,300 sh (New)
Jean-Marie Eveillard 1,173,300 sh (unchged)
» More
Q1 2014

EXEL Guru Trades in Q1 2014

Paul Tudor Jones 15,713 sh (New)
Louis Moore Bacon 250,000 sh (New)
Steven Cohen 17,977 sh (+25.71%)
Jean-Marie Eveillard 400,000 sh (-65.91%)
» More
Q2 2014

EXEL Guru Trades in Q2 2014

Jim Simons 1,658,150 sh (New)
Paul Tudor Jones Sold Out
Jean-Marie Eveillard Sold Out
Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 Sold Out $3.22 - $3.8 $ 1.72-50%0
Jean-Marie Eveillard 2014-03-31 Reduce -65.91%0.01%$3.38 - $8.24 $ 1.72-75%400000
John Burbank 2013-03-31 Sold Out 0.0019%$4.41 - $5.03 $ 1.72-63%0
John Burbank 2012-12-31 New Buy$4.33 - $5.32 $ 1.72-64%10753
Jean-Marie Eveillard 2012-09-30 Add 422.58%0.02%$4.28 - $6.45 $ 1.72-68%1175800
Jean-Marie Eveillard 2012-03-31 Add 125%$4.49 - $6.47 $ 1.72-66%225000
Jean-Marie Eveillard 2011-12-31 New Buy$3.95 - $7.81 $ 1.72-66%100000
Carl Icahn 2011-09-30 Sold Out 0.43%$5.5 - $9.22 $ 1.72-77%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 86.00
EXEL's P/B is ranked higher than
57% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. EXEL: 86.00 )
EXEL' s 10-Year P/B Range
Min: 2.53   Max: 1113
Current: 86

2.53
1113
P/S 15.26
EXEL's P/S is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.97 vs. EXEL: 15.26 )
EXEL' s 10-Year P/S Range
Min: 1.65   Max: 50.5
Current: 15.26

1.65
50.5
EV-to-EBIT -1.87
EXEL's EV-to-EBIT is ranked higher than
68% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EXEL: -1.87 )
EXEL' s 10-Year EV-to-EBIT Range
Min: -26.8   Max: 41.3
Current: -1.87

-26.8
41.3
Current Ratio 1.50
EXEL's Current Ratio is ranked higher than
58% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. EXEL: 1.50 )
EXEL' s 10-Year Current Ratio Range
Min: 0.84   Max: 9.35
Current: 1.5

0.84
9.35
Quick Ratio 1.49
EXEL's Quick Ratio is ranked higher than
61% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. EXEL: 1.49 )
EXEL' s 10-Year Quick Ratio Range
Min: 0.84   Max: 9.35
Current: 1.49

0.84
9.35

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.95
EXEL's Price/Median PS Value is ranked higher than
73% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.92 vs. EXEL: 1.95 )
EXEL' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 4.83
Current: 1.95

0.25
4.83
Earnings Yield (Greenblatt) -53.50
EXEL's Earnings Yield (Greenblatt) is ranked higher than
52% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. EXEL: -53.50 )
EXEL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.4   Max: 16.4
Current: -53.5

2.4
16.4
Forward Rate of Return (Yacktman) -25.10
EXEL's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. EXEL: -25.10 )
EXEL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -39.5   Max: -0.1
Current: -25.1

-39.5
-0.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EX9.Germany
Exelixis, Inc. formerly known as Exelixis Pharmaceuticals, Inc was incorporated in Delaware in November 1994. It is a biotechnology company that develops innovative therapies for cancer and other serious diseases and through its integrated drug discovery and development activities is building a portfolio of novel compounds that has the potential to be high-quality, differentiated pharmaceutical products that could make a meaningful difference in the lives of patients. The majority of programs focus on discovery and development of small molecule drugs for cancer. L184, It's most advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL184 is the advanced inhibitor of MET in clinical development and is being evaluated in the development program in collaboration with Bristol-Myers Squibb Company. The Company is currently conducting majority of the development activity for XL184, and its collaboration agreement provides for the sharing of development costs. A global phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer is currently enrolling. The established collaborations with pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, Genentech, Boehringer Ingelheim GmbH and GlaxoSmithKline that allows retaining economic participation in compounds and supporting additional development of its pipeline. The Company's collaborations generally fall into one of two categories: collaborations in which it co-develop compounds with a partner, share development costs and profits from Its potential competitors include major pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and government agencies.
» More Articles for EXEL

Headlines

Articles On GuruFocus.com
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs Dec 12 2008 

More From Other Websites
EXELIXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 16 2014
EXELIXIS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Oct 15 2014
Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014 Oct 14 2014
Exelixis (EXEL) Is in Oversold Territory: What's Next? Oct 03 2014
Ahead of the Bell: Exelixis shares soar Sep 29 2014
Ahead of the Bell: Exelixis shares soar Sep 29 2014
Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with... Sep 29 2014
EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Sep 25 2014
Why Exelixis (EXEL) Stock Might be a Great Pick Sep 18 2014
Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress Sep 17 2014
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9 Sep 08 2014
EXELIXIS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities Sep 05 2014
Exelixis Slumps 55% on Disappointing Cabozantinib Results Sep 03 2014
Exelixis (EXEL) Enters Oversold Territory Sep 03 2014
Exelixis Plunges On Drug Trial Failure; Investors See Potential Sep 02 2014
After the Exelixis Implosion, Is There Anything Left Ahead? Sep 02 2014
Why Exelixis (EXEL) Stock Plunged to a One-Year Low Today Sep 02 2014
Exelixis Drug Fails Pivotal Prostate Cancer Study Sep 02 2014
Ahead of the Bell: Exelixis shares tumble Sep 02 2014
Ahead of the Bell: Exelixis shares tumble Sep 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK